BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 21633925)

  • 1. Enhanced cell cycle perturbation and apoptosis mediate the synergistic effects of ST1926 and ATRA in neuroblastoma preclinical models.
    Di Francesco AM; Ubezio P; Torella AR; Meco D; Pierri F; Barone G; Cusano G; Pisano C; D'Incalci M; Riccardi R
    Invest New Drugs; 2012 Aug; 30(4):1319-30. PubMed ID: 21633925
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The novel atypical retinoid ST1926 is active in ATRA resistant neuroblastoma cells acting by a different mechanism.
    Di Francesco AM; Meco D; Torella AR; Barone G; D'Incalci M; Pisano C; Carminati P; Riccardi R
    Biochem Pharmacol; 2007 Mar; 73(5):643-55. PubMed ID: 17150196
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resistance to the atypical retinoid ST1926 in SK-N-AS cells selected the subline rAS-ST with enhanced sensitivity to ATRA mediated by not conventional mechanisms: DNA damage, G2 accumulation and late telomerase inhibition.
    Di Francesco AM; Cusano G; Franzese O; Orienti I; Falconi M; Vesci L; Riccardi R
    Toxicol In Vitro; 2015 Oct; 29(7):1628-38. PubMed ID: 26096597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor activity of the retinoid-related molecules (E)-3-(4'-hydroxy-3'-adamantylbiphenyl-4-yl)acrylic acid (ST1926) and 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid (CD437) in F9 teratocarcinoma: Role of retinoic acid receptor gamma and retinoid-independent pathways.
    Parrella E; Giannì M; Fratelli M; Barzago MM; Raska I; Diomede L; Kurosaki M; Pisano C; Carminati P; Merlini L; Dallavalle S; Tavecchio M; Rochette-Egly C; Terao M; Garattini E
    Mol Pharmacol; 2006 Sep; 70(3):909-24. PubMed ID: 16788091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The proteasome inhibitor bortezomib enhances ATRA-induced differentiation of neuroblastoma cells via the JNK mitogen-activated protein kinase pathway.
    Luo P; Lin M; Li L; Yang B; He Q
    PLoS One; 2011; 6(11):e27298. PubMed ID: 22087283
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modulation of survival signaling pathways and persistence of the genotoxic stress as a basis for the synergistic interaction between the atypical retinoid ST1926 and the epidermal growth factor receptor inhibitor ZD1839.
    Zanchi C; Zuco V; Lanzi C; Supino R; Zunino F
    Cancer Res; 2005 Mar; 65(6):2364-72. PubMed ID: 15781651
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ST1926, an orally active synthetic retinoid, induces apoptosis in chronic myeloid leukemia cells and prolongs survival in a murine model.
    Nasr RR; Hmadi RA; El-Eit RM; Iskandarani AN; Jabbour MN; Zaatari GS; Mahon FX; Pisano CC; Darwiche ND
    Int J Cancer; 2015 Aug; 137(3):698-709. PubMed ID: 25557649
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumor activity of the synthetic retinoid ST1926 on primary effusion lymphoma in vitro and in vivo models.
    Karam L; Houshaymi B; Abdel-Samad R; Jaafar M; Halloum I; Pisano C; Neipel F; Darwiche N; Abou Merhi R
    Oncol Rep; 2018 Feb; 39(2):721-730. PubMed ID: 29207182
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sensitization of ovarian carcinoma cells to the atypical retinoid ST1926 by the histone deacetylase inhibitor, RC307: enhanced DNA damage response.
    Zuco V; Benedetti V; De Cesare M; Zunino F
    Int J Cancer; 2010 Mar; 126(5):1246-55. PubMed ID: 19676051
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of LOX/COX inhibitors on cell differentiation induced by all-trans retinoic acid in neuroblastoma cell lines.
    Redova M; Chlapek P; Loja T; Zitterbart K; Hermanova M; Sterba J; Veselska R
    Int J Mol Med; 2010 Feb; 25(2):271-80. PubMed ID: 20043138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic efficacy of sorafenib and genistein in growth inhibition by down regulating angiogenic and survival factors and increasing apoptosis through upregulation of p53 and p21 in malignant neuroblastoma cells having N-Myc amplification or non-amplification.
    Roy Choudhury S; Karmakar S; Banik NL; Ray SK
    Invest New Drugs; 2010 Dec; 28(6):812-24. PubMed ID: 19777160
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The synthetic retinoid ST1926 as a novel therapeutic agent in rhabdomyosarcoma.
    Basma H; Ghayad SE; Rammal G; Mancinelli A; Harajly M; Ghamloush F; Dweik L; El-Eit R; Zalzali H; Rabeh W; Pisano C; Darwiche N; Saab R
    Int J Cancer; 2016 Mar; 138(6):1528-37. PubMed ID: 26453552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of resistance to the atypical retinoid, ST1926, in the lung carcinoma cell line H460 is associated with reduced formation of DNA strand breaks and a defective DNA damage response.
    Zuco V; Zanchi C; Lanzi C; Beretta GL; Supino R; Pisano C; Barbarino M; Zanier R; Bucci F; Aulicino C; Carminati P; Zunino F
    Neoplasia; 2005 Jul; 7(7):667-77. PubMed ID: 16026646
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cellular and pharmacological bases of the antitumor activity of a novel adamantyl retinoid, ST1926.
    Pisano C; Merlini L; Penco S; Carminati P; Zunino F
    J Chemother; 2004 Nov; 16 Suppl 4():74-6. PubMed ID: 15688616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of apoptosis and stress response in ovarian carcinoma cell lines treated with ST1926, an atypical retinoid.
    Zuco V; Zanchi C; Cassinelli G; Lanzi C; Supino R; Pisano C; Zanier R; Giordano V; Garattini E; Zunino F
    Cell Death Differ; 2004 Mar; 11(3):280-9. PubMed ID: 14657960
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The synthetic retinoid ST1926 attenuates prostate cancer growth and potentially targets prostate cancer stem-like cells.
    Bahmad HF; Samman H; Monzer A; Hadadeh O; Cheaito K; Abdel-Samad R; Hayar B; Pisano C; Msheik H; Liu YN; Darwiche N; Abou-Kheir W
    Mol Carcinog; 2019 Jul; 58(7):1208-1220. PubMed ID: 30883933
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor Effect of the Atypical Retinoid ST1926 in Acute Myeloid Leukemia and Nanoparticle Formulation Prolongs Lifespan and Reduces Tumor Burden of Xenograft Mice.
    El-Houjeiri L; Saad W; Hayar B; Aouad P; Tawil N; Abdel-Samad R; Hleihel R; Hamie M; Mancinelli A; Pisano C; El Hajj H; Darwiche N
    Mol Cancer Ther; 2017 Oct; 16(10):2047-2057. PubMed ID: 28619754
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting histone deacetylases (HDACs) and Wee1 for treating high-risk neuroblastoma.
    Hanmod SS; Wang G; Edwards H; Buck SA; Ge Y; Taub JW; Wang Z
    Pediatr Blood Cancer; 2015 Jan; 62(1):52-9. PubMed ID: 25308916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic induction of apoptosis in neuroblastoma cells using a combination of cytostatic drugs with interferon-gamma and TRAIL.
    Johnsen JI; Pettersen I; Ponthan F; Sveinbjørnsson B; Flaegstad T; Kogner P
    Int J Oncol; 2004 Dec; 25(6):1849-57. PubMed ID: 15547726
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retinoids induce differentiation and downregulate telomerase activity and N-Myc to increase sensitivity to flavonoids for apoptosis in human malignant neuroblastoma SH-SY5Y cells.
    Das A; Banik NL; Ray SK
    Int J Oncol; 2009 Mar; 34(3):757-65. PubMed ID: 19212680
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.